GlassScriptPhysician profile
Christopher M Leccese
NPI 1982670170
$1,743.12
in general payments reported to CMS, 2019-2025
14 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $390 · 2022: $466 · 2023: $333 · 2024: $414 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $887.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $501.99 | 2021-2025 | Wegovy |
| Abbvie INC. | $455.33 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $304.11 | 2021-2025 | Farxiga, Airsupra |
| Biohaven Pharmaceutical Holding Company LTD. | $138.60 | 2022 | |
| Lilly USA, LLC | $120.70 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $53.80 | 2023-2024 | |
| Xeris Pharmaceuticals, INC. | $40.39 | 2024 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $26.21 | 2025 | Rexulti |
| Exact Sciences Corporation | $21.51 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $19.01 | 2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.56 | 2024 | Caplyta |
| Amgen INC. | $16.04 | 2025 | Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.96 | 2021 | |
| Merck Sharp & Dohme LLC | $12.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Leccese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.